Background In our previous study, we established the novel concept of a non-neuronal cardiac cholinergic system–cardiomyocytes produce ACh in an autocrine and/or paracrine manner. Subsequently, we determined the biological significance of this system–it played a critical role in modulating mitochondrial oxygen consumption. However, its detailed mechanisms and clinical implications have not been fully investigated. Aim We investigated if this non-neuronal cardiac cholinergic system was upregulated by a modality other than drugs and if the activation of the system contributes to favorable outcomes. Results Choline acetyltransferase knockout (ChAT KO) cells with the lowest cellular ACh levels consumed more oxygen and had increased MTT activity and lower cellular ATP levels compared with the control cells. Cardiac ChAT KO cells with diminished connexin 43 expression formed poor cell–cell communication, evidenced by the blunted dye transfer. Similarly, the ChAT inhibitor hemicholinium-3 decreased ATP levels and increased MTT activity in cardiomyocytes. In the presence of a hypoxia mimetic, ChAT KO viability was reduced. Norepinephrine dose-dependently caused cardiac ChAT KO cell death associated with increased ROS production. In in vivo studies, protein expression of ChAT and the choline transporter CHT1 in the hindlimb were enhanced after ischemia-reperfusion compared with the contralateral non-treated limb. This local effect also remotely influenced the heart to upregulate ChAT and CHT1 expression as well as ACh and ATP levels in the heart compared with the baseline levels, and more intact cardiomyocytes were spared by this remote effect as evidenced by reduced infarction size. In contrast, the upregulated parameters were abrogated by hemicholinium-3. Conclusion The non-neuronal cholinergic system plays a protective role in both myocardial cells and the entire heart by conserving ATP levels and inhibiting oxygen consumption. Activation of this non-neuronal cardiac cholinergic system by a physiotherapeutic modality may underlie cardioprotection through the remote effect of hindlimb ischemia-reperfusion.
References
[1]
Kakinuma Y, Ando M, Kuwabara M, Katare RG, Okudela K, et al. (2005) Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha. FEBS Lett 579: 2111–2118.
[2]
Ando M, Katare RG, Kakinuma Y, Zhang D, Yamasaki F, et al. (2005) Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 112: 164–170.
[3]
Zhang Y, Kakinuma Y, Ando M, Katare RG, Yamasaki F, et al. (2006) Acetylcholine inhibits the hypoxia-induced reduction of connexin43 protein in rat cardiomyocytes. J Pharmacol Sci 101: 214–222.
[4]
Katare RG, Ando M, Kakinuma Y, Arikawa M, Handa T, et al. (2009) Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. J Thorac Cardiovasc Surg 137: 223–231.
[5]
Handa T, Katare RG, Kakinuma Y, Arikawa M, Ando M, et al. (2009) Anti-Alzheimer's drug, donepezil, markedly improves long-term survival after chronic heart failure in mice. J Card Fail 15: 805–811.
[6]
Katare RG, Ando M, Kakinuma Y, Arikawa M, Yamasaki F, et al. (2010) Differential regulation of TNF receptors by vagal nerve stimulation protects heart against acute ischemic injury. J Mol Cell Cardiol 49: 234–244.
[7]
Kakinuma Y, Furihata M, Akiyama T, Arikawa M, Handa T, et al. (2010) Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model. J Mol Cell Cardiol 48: 680–693.
[8]
Arikawa M, Katare RG, Kakinuma Y, Handa T, Ando M, et al.. (2007) Progression of ventricular dysfunction after myocardial infarction is prevented by anti-Alzheimer's disease drug, donepezil. Circulation 116: II_291.
[9]
Okazaki Y, Zheng C, Li M, Sugimachi M (2010) Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 60: 67–74.
[10]
Kakinuma Y, Katare RG, Arikawa M, Muramoto K, Yamasaki F, et al. (2008) A HIF-1alpha-related gene involved in cell protection from hypoxia by suppression of mitochondrial function. FEBS Lett 582: 332–340.
[11]
Kakinuma Y, Akiyama T, Sato T (2009) Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium. FEBS J 276: 5111–5125.
[12]
McNeil PL, Murphy RF, Lanni F, Taylor DL (1984) A method for incorporating macromolecules into adherent cells. J Cell Biol 98: 1556–1564.
[13]
Wessler I, Kirkpatrick CJ (2008) Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 154: 1558–1571.
[14]
Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979–2984.
[15]
Rapoport N, Marin AP, Timoshin AA (2000) Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch Biochem Biophys 384: 100–108.
[16]
Kirkpatrick CJ, Bittinger F, Nozadze K, Wessler I (2003) Expression and function of the non-neuronal cholinergic system in endothelial cells. Life Sci 72: 2111–2116.
[17]
Kawashima K, Fujii T (2004) Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci 9: 2063–2085.
[18]
Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, et al. (2005) Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33: 79–88.
[19]
Li M, Zheng C, Sato T, Kawada T, Sugimachi M, et al. (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109: 120–124.
[20]
Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, et al. (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 10: 884–891.
[21]
De Ferrari GM, Schwartz PJ (2011) Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Fail Rev 16: 195–203.
[22]
Hoover DB, Ganote CE, Ferguson SM, Blakely RD, Parsons RL (2004) Localization of cholinergic innervation in guinea pig heart by immunohistochemistry for high-affinity choline transporters. Cardiovasc Res 62: 112–121.
[23]
Kawano H, Okada R, Yano K (2003) Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels 18: 32–39.
[24]
Kuwabara M, Kakinuma Y, Katare RG, Ando M, Yamasaki F, et al. (2007) Granulocyte colony-stimulating factor activates Wnt signal to sustain gap junction function through recruitment of beta-catenin and cadherin. FEBS Lett 581: 4821–4830.
[25]
Kostin S, Hein S, Bauer EP, Schaper J (1999) Spatiotemporal development and distribution of intercellular junctions in adult rat cardiomyocytes in culture. Circ Res 85: 154–167.
[26]
Wu JC, Tsai RY, Chung TH (2003) Role of catenins in the development of gap junctions in rat cardiomyocytes. J Cell Biochem 88: 823–835.
[27]
Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, et al. (2007) Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 370: 575–579.
[28]
Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, et al.. (2007) Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 116 (11 Suppl): I98–105.
[29]
B？tker HE, Kharbanda R, Schmidt MR, B？ttcher M, Kaltoft AK, et al. (2010) Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375: 727–734.
[30]
Hausenloy DJ, Yellon DM (2008) Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 79: 377–386.
